Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 43598-426

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 43598-426). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cartonlabel (Cartonlabel)

Bortezomib For Injection 3.5 mg/vial powder, lyophilized for intravenous or subcutaneous use by Dr. Reddy's Laboratories, Inc. The carton includes storage instructions, reconstitution information, and dosage guidance, highlighting it as a single-dose cytotoxic agent. The label shows NDC 43598-426-60 and contains barcodes and distributor details indicating it is made in India.*

FDA Label Image

Figure1 (Figure1)

A survival curve graph comparing the percentage of patients over time (months) between two groups: Bortezomib-MP and MP. The y-axis shows the percentage of patients, and the x-axis displays time in months, with data points and patient numbers at risk noted below the axis. A p-value is indicated in the chart, suggesting statistical analysis between the groups.*

FDA Label Image

Figure2 (Figure2)

A Kaplan-Meier survival curve showing the percentage of patients over time (in months) comparing Bortezomib-MP and MP treatment groups. The chart includes number of patients at risk for each group at various time points and a p-value indicating statistical significance (p < 0.05) from a log-rank test.*

FDA Label Image

Figure3 (Figure3)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) for two treatment groups: Bortezomib and Dexamethasone. The graph shows the higher survival proportion for Bortezomib with corresponding p-value from a log-rank test, and includes annotations of patient numbers remaining at specific time points.*

FDA Label Image

Figure4 (Figure4)

A survival curve chart comparing the proportion of patients over time in days treated with Bortezomib versus Dexamethasone. The chart shows Bortezomib with a generally higher proportion of patients remaining compared to Dexamethasone. Patient counts at various time points are indicated below the x-axis. The p-value from log-rank test is noted as less than 0.05.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier survival curve comparing two treatment groups, VcR-CAP and R-CHOP, over time in months. The y-axis represents the percentage of patients, and the x-axis shows time up to 66 months. The chart includes a log rank test p-value <0.001 and a table below indicating the number of subjects at risk in each group at various time points.*

FDA Label Image

Figure6 (Figure6)

A survival curve chart depicting the percentage of subjects alive over time (months from randomization) for two treatment groups: VcR-CAP (solid line) and R-CHOP (dashed line). Below the chart is a table showing the number of subjects at risk at various time points for both groups. The chart includes a hazard ratio with 95% confidence interval (0.66, 0.51 to 0.85).*

FDA Label Image

Stickerlabel (Stickerlabel)

Label for Bortezomib for Injection powder showing preparation instructions for intravenous and subcutaneous administration. The intravenous section specifies adding 3.5 mL 0.9% sodium chloride to make a 1 mg/mL solution, with stickers labeled for vial and syringe. The subcutaneous section specifies adding 1.4 mL 0.9% sodium chloride to make a 2.5 mg/mL solution, with corresponding stickers.*

FDA Label Image

Chemical Structure (Structure)

Chemical structure of Bortezomib, showing its molecular framework with rings and functional groups consistent with the active ingredient Bortezomib used in injection form.*

FDA Label Image

Viallabel (Viallabel)

Label for Bortezomib For Injection 3.5 mg per vial, a lyophilized powder for intravenous or subcutaneous use. The label states it is a single-dose vial, must be diluted, and is a cytotoxic agent. Distributed by Dr. Reddy's Laboratories Inc., the label includes storage instructions, barcode, and indicates no preservative added.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.